Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

NCT ID: NCT04595370

Last Updated: 2024-11-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 153 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-01-26
• Study Completion Date: 2023-09-22

Brief Summary

The purpose of the study is to evaluate the efficacy and safety of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone and to assess the dose-response relationship, dapagliflozin alone and 3 doses of AZD9977 combined with dapagliflozin on urinary albumin to creatinine ratio (UACR). The study will be conducted in participants with heart failure (HF) with left ventricular ejection fraction (LVEF [below 60%]) and chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR [between ≥ 20 and ≤ 60 mL/min/1.73 m^2, with at least 20% of participants with eGFR ≥ 20 to <30 mL/min/1.73^2 and a maximum of 35% of participants with eGFR ≥ 45 mL/min/1.73 m^2]).

Detailed Description

After screening, eligible participants will undergo a run-in period where all participants receive dapagliflozin for up to 7 weeks depending on pre-study use of SGLT2i or not. At the end of the run-in period, eligible participants will be randomly assigned with a 1:1:1:1 ratio to receive once daily administration of one of the following 4 study treatments group for 12 weeks. To ensure blinding, the study treatment will be administered in the form of 3 oral capsules of AZD9977 or placebo and 1 oral tablet or dapagliflozin.

1. AZD9977 Dose A + dapagliflozin 10 mg

2. AZD9977 Dose B + dapagliflozin 10 mg

3. AZD9977 Dose C + dapagliflozin 10 mg

4. Dapagliflozin 10 mg

Participants will be randomized to one of the above treatment group, according to type 2 diabetes mellitus [T2DM (yes/no)] and eGFR (≥ 20 to <30 mL/min/1.73^2; or ≥ 30 to < 45 mL/min/1.73^2; or ≥45 mL/min/1.73^2).

The total duration of participation will be approximately 22 to 24weeks.

Conditions

Heart Failure; Chronic Kidney Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

AZD9977 Dose A + dapagliflozin 10 mg

Participants will receive once daily oral dose A of AZD9977 and 10 mg dapagliflozin for 12 weeks.

Group Type: EXPERIMENTAL

AZD9977

Intervention Type: DRUG

Participants will receive AZD9977 as per the arms they are randomized.

Dapagliflozin

Intervention Type: DRUG

Participants will receive dapagliflozin as per the arms they are randomized.

AZD9977 Dose B + dapagliflozin 10 mg

Participants will receive once daily oral dose B of AZD9977 and 10 mg dapagliflozin for 12 weeks.

Group Type: EXPERIMENTAL

AZD9977

Intervention Type: DRUG

Participants will receive AZD9977 as per the arms they are randomized.

Dapagliflozin

Intervention Type: DRUG

Participants will receive dapagliflozin as per the arms they are randomized.

AZD9977 Dose C + dapagliflozin 10 mg

Participants will receive once daily oral dose C of AZD9977 and 10 mg dapagliflozin for 12 weeks.

Group Type: EXPERIMENTAL

AZD9977

Intervention Type: DRUG

Participants will receive AZD9977 as per the arms they are randomized.

Dapagliflozin

Intervention Type: DRUG

Participants will receive dapagliflozin as per the arms they are randomized.

Dapagliflozin 10 mg

Participants will receive once daily oral dose of dapagliflozin 10 mg alone for 12 weeks.

Group Type: EXPERIMENTAL

Dapagliflozin

Intervention Type: DRUG

Participants will receive dapagliflozin as per the arms they are randomized.

Interventions

AZD9977

Participants will receive AZD9977 as per the arms they are randomized.

Intervention Type: DRUG

Dapagliflozin

Participants will receive dapagliflozin as per the arms they are randomized.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Participants are included in the study if any of the following criteria apply:

• Documented diagnosis of stable symptomatic HF (New York Heart Association class II-III) at screening, and a medical history of typical symptoms and signs of HF in those who are currently receiving loop diuretic treatment
• Left ventricular ejection fraction <60% documented by the most recent echocardiogram or cardiac magnetic resonance imaging within the last 12 months prior to screening
• Stable background treatment for HF, hypertension, diabetes mellitus or renal disease according to guidelines
• N-terminal-pro-brain natriuretic peptide (NT proBNP) ≥300 pg/mL for participants with sinus rhythm at screening; and NT proBNP ≥600 pg/mL for participants with atrial fibrillation/flutter at screening
• The eGFR ≥30 and ≤60 mL/min/1.73^2 (by CKD- EPI formula) and UACR ≥30 mg/g (3 mg/mmol) and <3000 mg/g (300 mg/mmol)
• Body mass index less than 40 kg/m^2
• Serum/plasma K+ level ≥ 3.5 and < 5.0 mmol/L within 10 days prior to randomization
• Serum/ plasma Na+ level within normal reference values within 10 days prior to randomization
• Systolic blood pressure should be at protocol defined range at randomization (Visit 3), with no change to antihypertensive treatments in previous 3 weeks
• Male or female of non-childbearing potential
• All participants must follow protocol defined contraceptives procedures

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

• Primary glomerulopathy, vasculitic renal disease, prior dialysis or unstable rapidly progressing renal disease, autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or anti-neutrophil cytoplasm antibody-associated vasculitis
• Participants with currently decompensated HF requiring hospitalization for optimization of HF treatment and are not on stable HF therapy at the time of enrollment
• HF due to cardiomyopathies
• High output HF (e.g., due to hyperthyroidism or Paget's disease)
• HF due to pericardial disease, congenital heart disease or clinically significant uncorrected primary cardiac valvular disease or planned cardiac valve repair/replacement
• Participants with uncontrolled diabetes mellitus (Glycated hemoglobin >10%)
• Participants with Type 1 diabetes mellitus
• Intermittent or persistent 2nd or 3rd degree atrioventricular block, sinus node dysfunction with clinically significant bradycardia or sinus pauses, not treated with a pacemaker
• History of any life-threatening cardiac dysrhythmia or uncontrolled ventricular rate in participants with atrial fibrillation or atrial flutter
• Acute coronary syndrome and/or elective/non-elective percutaneous cardiac interventions (within 3 months) prior to randomisation or is planned to undergo any of these procedures during the study
• Any major cardiovascular (eg, open chest, coronary artery bypass grafting or valvular repair/replacement) or major non-cardiovascular surgery within 3 months prior to randomisation or is planned to undergo any cardiovascular surgery during the study
• Heart transplantation or left ventricular assist device at any time or if these are planned
• Kidney or any organ transplantation or if these are planned
• Medical conditions associated with development of hyperkalaemia (Addison's disease )
• History or ongoing allergy/hypersensitivity, to sodium-glucose co-transporter-2 inhibitor (SGLT2i e.g., dapagliflozin, empagliflozin)
• Stroke, transient ischemic attack, carotid surgery, or carotid angioplasty within previous 3 months prior to randomisation
• Hepatic disease, including hepatitis and/or hepatic impairment (Child-Pugh class A-C), and aspartate aminotransferase or alanine transaminase or total bilirubin should be in protocol defined range at time of screening and/ or within 7 days prior to randomization
• Participants with newly detected pathological laboratory values or an ongoing disease condition
• If the participants clinical signs and symptoms consistent with COVID-19, and has been previously hospitalized with COVID-19 infection and did not fully recover their previous health status
• Previous randomization in the present study
• Prior medical treatment with an mineralocorticoid receptor antagonist where the medication was taken within 90 days prior to screening
• Current or prior treatment within 6 months prior to screening with cytotoxic therapy, immunosuppressive therapy, or other immunotherapy

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 130 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

John McMurray

Role: PRINCIPAL_INVESTIGATOR

University of Glasgow, United Kingdom

Locations

Research Site

Beverly Hills, California, United States

Research Site

Fountain Valley, California, United States

Research Site

Northridge, California, United States

Research Site

South Gate, California, United States

Research Site

Hialeah, Florida, United States

Research Site

Homestead, Florida, United States

Research Site

Jacksonville, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Ocala, Florida, United States

Research Site

Tampa, Florida, United States

Research Site

Augusta, Georgia, United States

Research Site

Columbus, Georgia, United States

Research Site

Baltimore, Maryland, United States

Research Site

Methuen, Massachusetts, United States

Research Site

St Louis, Missouri, United States

Research Site

The Bronx, New York, United States

Research Site

New Bern, North Carolina, United States

Research Site

Rapid City, South Dakota, United States

Research Site

Memphis, Tennessee, United States

Research Site

Houston, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Kingwood, Texas, United States

Research Site

McKinney, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

Sherman, Texas, United States

Research Site

Webster, Texas, United States

Research Site

Roeselare, , Belgium

Research Site

Pleven, , Bulgaria

Research Site

Plovdiv, , Bulgaria

Research Site

Plovdiv, , Bulgaria

Research Site

Plovdiv, , Bulgaria

Research Site

Sofia, , Bulgaria

Research Site

Sofia, , Bulgaria

Research Site

Sofia, , Bulgaria

Research Site

Sofia, , Bulgaria

Research Site

Sofia, , Bulgaria

Research Site

Veliko Tarnovo, , Bulgaria

Research Site

Peterborough, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Québec, Quebec, Canada

Research Site

Pardubice, , Czechia

Research Site

Prague, , Czechia

Research Site

Prague, , Czechia

Research Site

Uherské Hradiště, , Czechia

Research Site

Aarhus, , Denmark

Research Site

Herlev, , Denmark

Research Site

Svendborg, , Denmark

Research Site

Dresden, , Germany

Research Site

Frankfurt, , Germany

Research Site

Jena, , Germany

Research Site

Leipzig, , Germany

Research Site

Balatonfüred, , Hungary

Research Site

Budapest, , Hungary

Research Site

Budapest, , Hungary

Research Site

Debrecen, , Hungary

Research Site

Miskolc, , Hungary

Research Site

Orosháza, , Hungary

Research Site

Ahmedabad, , India

Research Site

Chennai, , India

Research Site

Kolkata, , India

Research Site

Pune, , India

Research Site

Roma, , Italy

Research Site

Chūōku, , Japan

Research Site

Hamada-shi, , Japan

Research Site

Hamamatsu, , Japan

Research Site

Hanyu-shi, , Japan

Research Site

Itabashi-ku, , Japan

Research Site

Kasugai-shi, , Japan

Research Site

Kawaguchi, , Japan

Research Site

Kishiwada-shi, , Japan

Research Site

Kobe, , Japan

Research Site

Kobe, , Japan

Research Site

Matsudo-Shi, , Japan

Research Site

Matsumoto-shi, , Japan

Research Site

Ono, , Japan

Research Site

Osaka, , Japan

Research Site

Sapporo, , Japan

Research Site

Sayama, , Japan

Research Site

Takasago-shi, , Japan

Research Site

Takasaki-shi, , Japan

Research Site

Ueda-shi, , Japan

Research Site

Yokohama, , Japan

Research Site

Yokohama, , Japan

Research Site

Yokohama, , Japan

Research Site

Kaunas, , Lithuania

Research Site

Klaipėda, , Lithuania

Research Site

Šiauliai, , Lithuania

Research Site

Vilnius, , Lithuania

Research Site

Gdansk, , Poland

Research Site

Gdansk, , Poland

Research Site

Katowice, , Poland

Research Site

Lodz, , Poland

Research Site

Lodz, , Poland

Research Site

Lodz, , Poland

Research Site

Lublin, , Poland

Research Site

Ostrowiec Świętokrzyski, , Poland

Research Site

Oświęcim, , Poland

Research Site

Oława, , Poland

Research Site

Pabianice, , Poland

Research Site

Poznan, , Poland

Research Site

Skorzewo, , Poland

Research Site

Sopot, , Poland

Research Site

Szczecin, , Poland

Research Site

Torun, , Poland

Research Site

Warsaw, , Poland

Research Site

Kazan', , Russia

Research Site

Kazan, Tatarstan, , Russia

Research Site

Kemerovo, , Russia

Research Site

Moscow, , Russia

Research Site

Moscow, , Russia

Research Site

Moscow, , Russia

Research Site

Moscow, , Russia

Research Site

Saint Petersburg, , Russia

Research Site

Saint Petersburg, , Russia

Research Site

Saint Petersburg, , Russia

Research Site

Saint Petersburg, , Russia

Research Site

Banská Bystrica, , Slovakia

Research Site

Brezno, , Slovakia

Research Site

Lučenec, , Slovakia

Research Site

Prešov, , Slovakia

Research Site

Svidník, , Slovakia

Research Site

Trenčín, , Slovakia

Research Site

Busan, , South Korea

Research Site

Gangwon-do, , South Korea

Research Site

Seongnam-si, , South Korea

Research Site

Seoul, , South Korea

Research Site

Seoul, , South Korea

Research Site

Seoul, , South Korea

Research Site

A Coruña, , Spain

Research Site

Barcelona, , Spain

Research Site

El Palmar, , Spain

Research Site

Madrid, , Spain

Research Site

Málaga, , Spain

Research Site

Santiago(A Coruña), , Spain

Research Site

Seville, , Spain

Research Site

Valencia, , Spain

Research Site

Valencia, , Spain

Research Site

Gothenburg, , Sweden

Research Site

Stockholm, , Sweden

Research Site

Stockholm, , Sweden

Research Site

Uppsala, , Sweden

Research Site

Kaohsiung City, , Taiwan

Research Site

Taichung, , Taiwan

Research Site

Taipei, , Taiwan

Research Site

Taipei, , Taiwan

Research Site

Taipei, , Taiwan

Research Site

Bangkok, , Thailand

Research Site

Bangkok, , Thailand

Research Site

Chaingmai, , Thailand

Research Site

Khon Kaen, , Thailand

Research Site

Adana, , Turkey (Türkiye)

Research Site

Kocaeli, , Turkey (Türkiye)

Research Site

Ivano-Frankivsk, , Ukraine

Research Site

Kharkiv, , Ukraine

Research Site

Kyiv, , Ukraine

Countries

United States; Belgium; Bulgaria; Canada; Czechia; Denmark; Germany; Hungary; India; Italy; Japan; Lithuania; Poland; Russia; Slovakia; South Korea; Spain; Sweden; Taiwan; Thailand; Turkey (Türkiye); Ukraine

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D6402C00001&amp;attachmentIdentifier=fddab4bc-57ea-45ba-b963-ae71d1eb0839&amp;fileName=Redacted_CSR_Synopsis_D6402C00001.pdf&amp;versionIdentifier=

Redacted CSR Synopsis\_D6402C00001

Other Identifiers

2020-003126-23

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

D6402C00001

Identifier Type: -

Identifier Source: org_study_id